Data Article

Data in support of optimized production of angiotensin-I converting enzyme inhibitory peptides derived from proteolytic hydrolysate of bitter melon seed proteins

Anugerah Dany Priyanto a, b, Robert J. Doerksen c, Chi-I Chang a, Wang-Chou Sung d, Simon Bambang Widjanarko b, Joni Kusnadi b, Ya-Chi Lin a, Ting-Chin Wang a, Jue-Liang Hsu a, e, f, *

a Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan
b Department of Food Science, Faculty of Agricultural Technology, University of Brawijaya, Malang 65145, Indonesia
c Department of BioMolecular Sciences and Research Institute of Pharmaceutical Sciences, University of Mississippi, MS 38677, United States
d Vaccine Research and Development Center, National Health Research Institutes, Miaoli 35053, Taiwan
e Research Center for Tropic Agriculture, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan
f Research Center for Austronesian Medicine and Agriculture, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan

ARTICLE INFO

Article history:
Received 4 September 2015
Received in revised form 21 September 2015
Accepted 24 September 2015
Available online 9 October 2015

ABSTRACT

VY-7 has been demonstrated as a potent ACE inhibitory peptide in the previous study [1]. In this article, we provide accompanying data about the identification of bitter melon seed proteins (BMSPs), and quantitative analysis and optimized production of VY-7 in BMSPs hydrolysate.

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

DOI of original article: http://dx.doi.org/10.1016/j.jprot.2015.08.018
* Corresponding author at: Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan.
E-mail address: jlhsu@mail.npust.edu.tw (J.-L. Hsu).

http://dx.doi.org/10.1016/j.dib.2015.09.038
2352-3409/© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Specifications table

| Subject area | Chemistry, Biology |
|--------------|--------------------|
| More specific subject area | Angiotensin-I converting enzyme inhibitory peptides |
| Type of data | Tables of identified sequences and peptide yield enhancement; text description of the data; and figures of ACE inhibitory activities, LC–MS/MS and HPLC for BMSP hydrolysates |
| How data was acquired | Mass spectrometry, database search, ACE inhibitory assay, SDS-PAGE |
| Data format | Raw, filtered, and analyzed |
| Experimental factors | These are described in the text description of the data |
| Experimental features | These are described in the text description of the data |
| Data source location | Pingtung, Taiwan |
| Data accessibility | Data is supplied in this article |

2. Value of the data

- Peptides identified from hydrolysate of bitter melon (*Momordica charantia*) seed proteins could be developed into food products.
- The approach we took to quantitative analysis of active peptides using LC–MS/MS under the mode of multiple reaction monitoring could be useful to others.
- Others interested in how to optimize peptide yield from natural sources could learn from our approach to tuning hydrolysis conditions, monitored by HPLC.

3. Data

ACE inhibitory activities of five BMSP hydrolysates (which were derived from trypsin, α-chymotrypsin, pepsin, alcalase, and thermolysin) were evaluated using *in vitro* ACE inhibitory assay. The identified peptides were analyzed using LC–MS/MS. The yields of VY-7 at various hydrolysis conditions were examined using LC–MS/MS (MRM mode) and HPLC.

4. Experimental design, materials and methods

4.1. Peptide identification using in-gel digestion, LC–MS/MS analysis and database matching

Bitter melon seed proteins (BMSPs) were separated using SDS-PAGE to give several distinct bands [1]. Five protein bands were in-gel digested by trypsin and the resulting peptides were analyzed using LC–MS/MS and Mascot database search. The data indicated that momordin A (protein source of VY-7) was located at the most intensive band positions with molecular weight around 28 kDa. The identified peptides derived from this protein are summarized in Table S1 in Supplementary information.
4.2. ACE inhibitory assay of BMSPs hydrolysates derived from different enzymes.

BMSPs were digested using different proteolytic enzymes, trypsin (pH 8, 37 °C), α-chymotrypsin (pH 8, 37 °C), pepsin (pH 1.5, 37 °C), alcalase (pH 8, 50 °C), and thermolysin (pH 8, 60 °C). The hydrolysates derived from different enzymes were ultrafiltrated using 3 kDa MWCO ultrafiltration membranes and the resulting filtrates were lyophilized and subjected individually to ACE inhibitory assay according to previous report [2]. Data is shown in Fig. 1.
4.3. Quantitative analysis of VY-7 in BMSPs hydrolysate using LC–MS/MS.

To determine the content of VY-7 in crude BMSPs hydrolysate, multiple reaction monitoring (MRM) was performed in LC–MS/MS analysis of BMSPs hydrolysate, similar to our previous report [3]. The MRM transition of VY-7 was set to be \( m/z \) 709.7 > 181.7 and 243.8 under a collision-induced

Table 1

| E/S ratio | Hydrolysis time (h) | Temperature (°C) | Peptide amount (μg/mg) |
|-----------|---------------------|------------------|------------------------|
| 1:50      | 12                  | 60               | 10.20 ± 0.84           |
| 1:100     | 14.89 ± 0.44        |
| 1:200     | 10.65 ± 0.85        |
| 1:400     | 4.21 ± 0.44         |
| 1:800     | 2.78 ± 0.05         |
| 1:100     | 2.05 ± 0.25         |
|           | 3.96 ± 0.79         |
|           | 7.77 ± 0.48         |
|           | 10.34 ± 0.68        |
|           | 2.48 ± 0.26         |
| 1:50      | 4.42 ± 0.23         |
| 1:100     | 8.05 ± 0.27         |
| 1:200     | 1.49 ± 0.05         |

Fig. 3. HPLC chromatograms of the BMSP thermolysin hydrolysate digested using condition (A) before; and (B) after optimization. The target peptide VY-7 is located between the two dotted lines.

4.3. Quantitative analysis of VY-7 in BMSPs hydrolysate using LC–MS/MS.

To determine the content of VY-7 in crude BMSPs hydrolysate, multiple reaction monitoring (MRM) was performed in LC–MS/MS analysis of BMSPs hydrolysate, similar to our previous report [3]. The MRM transition of VY-7 was set to be \( m/z \) 709.7 > 181.7 and 243.8 under a collision-induced
dissociation (CID) energy of 40 V. Using the same LC–MS/MS condition, the calibration curve was established based on six standard peptide solutions at concentrations from 50 pg/µL to 25 ng/µL. The content of VY-7 in each BMSPs hydrolysate was determined according to its peak area in the MRM chromatogram. The full scan and VY-7 MRM chromatogram of BMSP hydrolysate are shown in Fig. 2. Moreover, the standard peptide was also spiked into crude BMSPs hydrolysate to confirm the quantification of the results based on the retention time and the spike yield (based on peak area), as shown in Fig. 2(C).

4.4. Optimization of target peptide formation by tuning hydrolysis conditions.

To increase the yield of VY-7, the hydrolysis conditions, in terms of enzyme-to-protein ratios (w/w) (1/50, 1/100, 1/200, 1/400, and 1/800), hydrolysis times (1, 3, 6, 9, 12, and 15 h) and temperatures of incubation (40, 50, 60, and 70 °C), were optimized, using an approach similar to our previous report [4]. The optimum condition was defined as the condition which could produce the highest amount of target peptide. The yield of VY-7 in each hydrolysis condition was calculated based on MRM analysis, as mentioned in Section 4.3. The results are shown in Table 1. Using the optimum condition, an E/S ratio of 1:100 (w/w) was obtained with hydrolysis time of 12 h at 60 °C and 14.89 ± 0.88 µg of VY-7 can be formed from 1 mg of BMSPs. The HPLC peptide patterns before and after hydrolysis optimization are shown in Fig. 3. The yield of target peptide was dramatically improved when the optimum conditions were used.

Acknowledgments

This work was financially supported by Taiwan Ministry of Science and Technology (MOST) Grants (MOST 104-2113-M-020-001 for Dr. Jue-Liang Hsu). We also appreciate the instrument support by Research Center for Active Natural Products Development in NPUST.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.dib.2015.09.038.

References

[1] A.D. Priyanto, R.J. Doerksen, C.I. Chang, W.C. Sung, S.B. Widjanarko, J. Kusnadi, Y.C. Lin, T.C. Wang, J.L. Hsu, Screening, discovery, and characterization of angiotensin-I converting enzyme inhibitory peptides derived from proteolytic hydrolysate of bitter melon seed proteins, J. Proteomics 128 (2015) 424–435. http://dx.doi.org/10.1016/j.jprot.2015.08.018.
[2] D.W. Cushman, H.S. Cheung, E.F. Sabo, M.A. Ondetti, Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids, Biochemistry 16 (25) (1997) 5484–5491.
[3] R.D. Rawendra, Chen S.H. Aisha, C.I. Chang, W.L. Shih, T.C. Huang, M.H. Liao, J.L. Hsu, Isolation and characterization of a novel angiotensin-converting enzyme-inhibitory tripeptide from enzymatic hydrolysate of soft-shelled turtle (Pelodiscus sinensis) egg white: in vitro, in vivo, and in silico study, J. Agric. Food Chem. 62 (50) (2014) 12178–12185.
[4] R.D. Rawendra, Aisha, C.I. Chang, Aulanni'am, H.H. Chen, T.C. Huang, J.L. Hsu, A novel angiotensin converting enzyme inhibitory peptide derived from proteolytic digest of Chinese soft-shelled turtle egg white proteins, J. Proteomics 94 (2013) 359–369.